Key Takeaways:
- Jefferies upgrades Abbott Laboratories (ABT, Financial) to "Buy" following robust Q2 performance.
- Wall Street analysts forecast an average price target of $143.05 for ABT.
- Current analysis indicates a potential downside based on GuruFocus GF Value estimates.
Abbott Laboratories (ABT) received a significant upgrade from Jefferies, moving from a "Hold" to a "Buy" rating, as the firm provided an optimistic outlook on Abbott's long-term growth potential following an impressive Q2 earnings report. With revenues reaching $11.1 billion—beating expectations by $80 million—and an adjusted EPS of $1.26, Jefferies has set a price target of $145, indicating confidence in the company's trajectory despite recent challenges.
Wall Street Analysts Forecast
Examining the insights from 24 analysts over the next year, Abbott Laboratories (ABT, Financial) has an average price target of $143.05. This forecast includes a high prediction of $159.00 and a low of $120.12, suggesting a potential upside of 14.74% from the current stock price of $124.67. For a more comprehensive perspective, visit the Abbott Laboratories (ABT) Forecast page.
Regarding analyst consensus, Abbott Laboratories (ABT, Financial) holds an "Outperform" recommendation, with an average rating of 2.1 across 29 brokerage firms. This rating is situated on a scale where 1 denotes a Strong Buy and 5 signifies a Sell, underscoring positive expectations from the investment community.
On the other hand, GuruFocus estimates a GF Value for Abbott Laboratories (ABT, Financial) at $121.36 over the next year, indicating a possible downside of 2.66% from the current price of $124.67. GF Value represents GuruFocus's assessment of a stock's fair trading value, calculated using historical trading multiples, past business growth, and future performance projections. For more detailed analysis, visit the Abbott Laboratories (ABT) Summary page.
